What Is Semaglutide

Semaglutide is a synthetic peptide that mimics glucagon-like peptide-1 (GLP-1), a hormone produced in the gut after eating. By binding to GLP-1 receptors in the pancreas, brain, and other tissues, it enhances insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite. It is approved for the treatment of type 2 diabetes and, at higher doses, for chronic weight management in adults with obesity or overweight.

Excess body fat, particularly visceral adiposity, is one of the strongest accelerators of biological aging. It drives chronic low-grade inflammation, insulin resistance, dyslipidemia, and elevated risk of cardiovascular disease, type 2 diabetes, and certain cancers. Each of these conditions independently shortens healthspan and lifespan. Interventions that meaningfully reduce adiposity have the potential to slow or partially reverse these cascading metabolic harms.

Semaglutide has attracted attention in the longevity space because it produces clinically significant weight reduction and appears to offer cardiovascular benefits that go beyond what weight loss alone would predict. Large outcome trials have shown reductions in major adverse cardiac events among users with pre-existing cardiovascular disease. GLP-1 receptors are also expressed in brain tissue, and early research is exploring whether semaglutide may influence neuroinflammation and neurodegeneration, though this remains speculative. The compound sits at an intersection of metabolic medicine, cardiovascular prevention, and emerging aging biology.

Semaglutide is a modified version of human GLP-1, engineered with amino acid substitutions and a fatty acid side chain that allow it to bind tightly to albumin in the blood. This albumin binding dramatically extends its half-life from roughly two minutes (for native GLP-1) to approximately one week, making once-weekly dosing feasible. The structural modifications also protect the molecule from degradation by dipeptidyl peptidase-4 (DPP-4), the enzyme that rapidly inactivates endogenous GLP-1.

Once circulating, semaglutide binds to GLP-1 receptors on pancreatic beta cells, stimulating glucose-dependent insulin secretion. This means insulin release is amplified when blood sugar is elevated but not when it is already normal, reducing the risk of hypoglycemia. Simultaneously, it suppresses glucagon secretion from alpha cells, which lowers hepatic glucose output. In the gastrointestinal tract, semaglutide slows gastric motility, prolonging the sensation of fullness after meals.

The appetite-suppressing effect is primarily central. GLP-1 receptors in the hypothalamus and brainstem, particularly in areas governing satiety and reward, are activated by semaglutide. This reduces hunger signals and, according to neuroimaging studies, diminishes the hedonic drive toward calorie-dense foods. The net result is a sustained reduction in caloric intake that, combined with peripheral metabolic effects, produces the observed weight loss. Emerging preclinical work suggests additional effects on inflammatory signaling pathways and endothelial function, though these mechanisms are less well characterized in humans.

Semaglutide is available in two primary delivery forms. The subcutaneous injection, administered once weekly using a prefilled pen, is the most widely used format and is marketed under different brand names depending on the indication (type 2 diabetes versus chronic weight management). The injectable route provides reliable bioavailability and bypasses first-pass metabolism in the liver.

An oral formulation also exists, using a co-formulated absorption enhancer (salcaprozate sodium, or SNAC) that protects the peptide from gastric degradation and facilitates absorption across the stomach lining. The oral version requires specific dosing conditions: it must be taken on an empty stomach with no more than four ounces of plain water, and the patient must wait at least 30 minutes before eating, drinking, or taking other oral medications. Bioavailability of the oral form is considerably lower than the injectable, which is why the oral doses are expressed in milligrams rather than the microgram-scale doses used subcutaneously. Compounded semaglutide, available through some pharmacies, does not carry the same regulatory oversight as branded products, and its pharmacokinetic profile may differ.

Dosing follows a structured escalation protocol designed to improve gastrointestinal tolerability. For the subcutaneous injection used in weight management, the typical schedule begins at 0.25 mg weekly for four weeks, increases to 0.5 mg, then to 1.0 mg, then 1.7 mg, and finally reaches the 2.4 mg maintenance dose. Each step lasts approximately four weeks, so the full titration spans about 16 to 20 weeks. For the diabetes indication, the target maintenance dose is typically lower, at 1.0 mg or 2.0 mg weekly.

The oral formulation begins at 3 mg daily for 30 days, then increases to 7 mg, with a further increase to 14 mg if additional glycemic control is needed. Some patients tolerate dose escalation without significant nausea; others may need to remain at an intermediate dose for longer before advancing. Dose adjustments should be guided by clinical response, side effect burden, and metabolic markers rather than adherence to a rigid timeline. There is no evidence supporting doses above the approved range, and higher doses increase the frequency of adverse effects without established additional benefit.

The branded products (manufactured under FDA oversight) undergo rigorous quality control, including verification of peptide purity, sterility, and correct concentration. For individuals using FDA-approved prefilled pens, quality is generally assured by the manufacturer's regulatory obligations and lot-testing requirements.

The situation is different with compounded semaglutide, which has become widely available through compounding pharmacies and telehealth platforms. The FDA has raised concerns about compounded versions, including reports of products containing salt forms of semaglutide (such as semaglutide sodium) that are not the same as the base molecule used in approved products. Patients considering compounded semaglutide should verify that the pharmacy holds current state licensing and accreditation from a recognized body such as PCAB (Pharmacy Compounding Accreditation Board), that the product has undergone third-party potency and sterility testing, and that the prescribing clinician is monitoring treatment with appropriate lab work. The absence of these safeguards introduces risks that are separate from the pharmacology of the drug itself.

The clinical evidence base for semaglutide is substantial compared to most compounds discussed in the longevity space. Multiple large, randomized, placebo-controlled trials have demonstrated its efficacy for glycemic control in type 2 diabetes and for weight reduction in obesity. The STEP trial program, which enrolled thousands of participants, established the weight-loss profile of the 2.4 mg weekly subcutaneous dose. The SELECT trial, a cardiovascular outcomes study in people with overweight or obesity and established cardiovascular disease but without diabetes, reported a statistically significant reduction in major adverse cardiovascular events. This was notable because it extended the cardiovascular benefit signal beyond the diabetic population.

Gaps remain in several areas relevant to longevity. Long-term data beyond two to three years of continuous use are limited, making it unclear how sustained the metabolic benefits are and whether new safety signals emerge with extended exposure. The degree of lean mass loss during semaglutide-induced weight reduction is a concern, particularly for older adults at risk of sarcopenia; countermeasures like resistance training and adequate protein intake are recommended but not yet well studied in combination with the drug in controlled settings. Preclinical observations regarding neuroprotection and reduced neuroinflammation are intriguing but have not translated into clinical trial endpoints. The effect on biological aging biomarkers, such as epigenetic clocks, has not been formally assessed in published trials.

The most common adverse effects are gastrointestinal, including nausea, vomiting, diarrhea, and constipation, which typically peak during dose escalation. More serious but less frequent risks include pancreatitis, gallbladder disease (gallstones and cholecystitis), and potential worsening of diabetic retinopathy in people with pre-existing eye disease. Rodent studies showed an increased incidence of thyroid C-cell tumors, leading to a boxed warning against use in individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Loss of lean body mass alongside fat loss can be clinically meaningful, especially in older adults, and should be actively monitored and countered. Semaglutide is a prescription medication, and sourcing from compounding pharmacies outside the FDA-approved supply chain introduces quality and sterility risks that are not trivial.